Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Savolitinib · HMPL-504, AZD-6094

Small molecule · Inhibitor of c-Met receptor tyrosine kinase (hepatocyte growth factor receptor) (MET) · developed by ASTRAZENECA

Phase 3 Most advanced trial
AZN Developer
1 Registered trials

What is Savolitinib?

Savolitinib is an orally bioavailable small molecule that binds c-Met receptor tyrosine kinase in an ATP-competitive manner and inhibits its activation, disrupting c-Met signal transduction. It is being studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
HMPL-504, AZD-6094
Drug type
Small molecule
Targets
c-Met receptor tyrosine kinase (hepatocyte growth factor receptor) (MET)
Mechanism
Inhibitor of c-Met receptor tyrosine kinase (hepatocyte growth factor receptor) (MET)
Pathways
c-Met signal transduction, tumor cell proliferation, survival and invasion, tumor angiogenesis
Therapy area
Oncology
Developer
ASTRAZENECA (AZN)
Also in trials of
HCM
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
2A2DA6857R

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05009836 Phase 3 Non-small Cell Lung Cancer Active not recruiting HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-small Cell Lung Cancer

Other drugs acting on MET

More from ASTRAZENECA

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Savolitinib

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.